Stem cell therapy for Parkinson's disease: where do we stand?
Laurent Roybon1, Nicolaj S Christophersen, Patrik Brundin
1Section for Neuronal Survival, Wallenberg Neuroscience Center, Lund University, BMC A10, 22184 Lund, Sweden. laurent.roybon@mphy.lu.se
Abstract:
A major neuropathological feature of Parkinson's disease (PD) is the loss of nigrostriatal dopaminergic neuron. Patients exhibit motor symptoms, including bradykinesia, rigidity, and tremor. Neural grafting has been reported to restore striatial dopaminergic neurotransmission and induce symptomatic relief. The major limitation of cell replacement therapy for PD is the shortage of suitable donor tissue. The present review describes the possible sources of cells, including embryonic stem cells and somatic adult stem cells, both of which potentially could be used in cell therapy for PD, and discusses the advantages and disadvantages of each cell type.
Related Concept Videos
EPS and iPS Cells in Disease Research
iPS Cell Differentiation
Induced Pluripotent Stem Cells
Induced Pluripotent Stem Cells
Somatic cells are...
Parkinson's Disease: Treatment
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...
Parkinson's Disease: Overview


